Moderna Inc MRNA
News
Moderna says new-generation COVID vaccine more effective than Spikevax in adults 18 and over
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Moderna's combo COVID and flu vaccine works better than stand-alone shots on the market, study finds
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
Moderna Files With FDA for Updated Covid Shot
Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Moderna Drug Candidate Tapped for FDA Rare-Disease Pilot Program
Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Merck, Moderna Drug Combo Shows Improved Survival in Skin Cancer Trial
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna wins second product approval with RSV vaccine
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
New U.S. bird-flu case is first with respiratory symptoms, CDC says
Moderna's stock climbs on report that bird-flu vaccine funding is near